These awards will help pioneer and accelerate novel drug development for the treatment of Parkinson’s, providing researchers the opportunity to plug essential gaps in existing datasets to get their projects/compounds ready to enter full scale drug discovery with an industry partner or the Parkinson’s Virtual Biotech.
We are looking for projects that will have a clear focus on translational drug development to make a difference to those affected by Parkinson’s.
The deadline for full applications is Thursday 26 October 2023, by 4pm for applicants who are successful at the preproposal stage.
Round 1 - 2024
The deadline for preproposal applications is Monday 15 January 2024, by 4pm.
The deadline for full applications is Tuesday 12 March 2024, by 4pm for applicants who are successful at the preproposal stage.
Round 2 - 2024
The deadline for preproposal applications is Tuesday 3 September 2024, by 4pm.
The deadline for full applications is Thursday 31 October 2024, by 4pm for applicants who are successful at the preproposal stage.
Please email [email protected] for a copy of the preproposal application.
Sign up for our virtual workshop on Friday 8 December 2023 at 10am to find out more about this funding scheme and discuss your research ideas with members of the Parkinson's UK research and drug discovery team.
The duration of a grant is up to a maximum of 12 months.
There is no minimum value and the maximum award amount is £100,000.
For projects involving in vivo work, a duration of 12 to 18 months and award amount up to £150,000 will be considered.
Grants are tenable only at a UK university, NHS Trust or small start-up biotech companies.
Principal applicants should hold employment contracts that extend beyond the period of the grant.
Co-applicants and collaborators may be based at institutions outside the UK or biotech companies.
Apply for a Drug Accelerator Award
Get updates on grants
Be the first to find out about funding, events, news and opportunities in the world of research by signing up to Synapse - our enewsletter for the Parkinson's research community.